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Abstract: A four-year prospective study was carried out to determine the incidence and rate 
of development of resistance by common urinary tract infection (UTI) pathogens to quinolone 
antimicrobial agents. Results show that there is high intrinsic resistance to the quinolones 
among strains of Pseudomonas aeruginosa (43.4%), Escherichia coli (26.3%), and Proteus spp. 
(17.1%). Over four years, rising rates of resistance were observed in P. aeruginosa (14.6% 
increase), Staphylococcus aureus (9.8%), and E. coli (9.7%). The highest potency was exhibited 
by ciprofloxacin (91.2%), levofloxacin (89.2%), and moxifloxacin (85.1%), while there were 
high rates of resistance to nalidixic acid (51.7%) and pefloxacin (29.0%). Coliforms, particularly 
E. coli (45%), remain the most prevalent causative agents of UTI while females within the 
age range of 20–50 years were most vulnerable to UTI.
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Introduction
Urinary tract infections (UTI) could be defined as the persistent presence within 
the urinary tract of actively multiplying microorganisms. UTI implies both micro-
bial colonization of the urine and invasion of the lower or upper urinary tract by 
microorganisms.1 It is an infection with more than 100,000 organisms per milliliters 
in the mid-stream urine samples.2
Urinary tract infection is the most common disease of the urinary tract and it is a 
major cause of morbidity in both the hospital and the community.3 The most common 
causes of UTI are bacteria, and less often viruses, yeasts, or other intracellular 
microorganisms.4 According to Bohnson,5 bacteriuria may be completely asymptomatic 
or remain localized in the bladder without the development of renal infection. Urine 
secreted by normal kidneys is sterile and remains so while it travels to the bladder, 
however, normal urine is known to have microbial flora and any voided urine in normal 
patients may therefore contain thousands of bacteria per milliliter derived from this 
normal flora. In order to differentiate this smaller number of microorganisms from the 
larger number of microorganisms commonly found in UTIs, it is essential to count the 
number of bacteria present in freshly collected specimens by appropriate methods.6
Therapy of infectious diseases with antimicrobial agents is very dynamic as a 
result of increase in bacterial resistance to most available antimicrobial agents. Hence 
most bacterial infections, especially hospital-acquired infections, are becoming more 
and more difficult to treat. Bacterial resistance has been reported to almost every 
antimicrobial drug available; hence this study evaluated the susceptibility pattern of International Journal of General Medicine 2009:2 172
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the newer and presumed more efficient antibiotics which 
have been reported to be effective in the treatment of lots of 
ailments including UTI.6 A report on the susceptibility pat-
tern of bacteria isolated from UTI cases to quinolones will 
further enhance the treatment of UTI, which has become 
difficult to treat due to multidrug resistance. Such multidrug 
resistance has become increasingly common throughout 
the world and has become expensive to treat.7 It therefore 
becomes imperative to check the potency of quinolones 
against some principal pathogens isolated in UTI cases. 
In vitro tests of the potency of antimicrobial agents provide 
a means of obtaining rapid and inexpensive information on 
the treatment of UTI.8,9
In Nigeria, UTI is prevalent among men and women, but is 
more common among women, especially during pregnancy.9 
Unrecognized UTI in infancy and childhood may have 
serious long-term effects and chronic pyelonephritis may 
occur in adults. However, the infection occurs in all persons 
regardless of sex or age with particular impact on the young 
and the very elderly.10 Sexually active females are also 
more predisposed to UTI than their male counterparts.9,11 
In later life, UTI is more common among men until the age 
of prostatic hypertrophy (above 40 years of age).6
For many years, pathogens associated with uncompli-
cated UTI have remained constant, with Escherichia coli 
identified as the etiological agent in about 75%–90% of 
infections.12 Five to 10% of uncomplicated cases are caused 
by Staphylococcus saprophyticus13 with Klebsiella, Proteus, 
Enterococcus, and Pseudomonas species seen in much 
smaller percentages.14–16
Etiological agents of infectious disease and their sensitiv-
ity to antimicrobial drugs used for their control have always 
been of interest in clinical medicine. Various studies have 
reported the causative bacterial agents of many cases of 
UTIs seen in Nigerian hospitals and their in vitro sensitivity 
to antimicrobial agents.17,18 One common concern amongst 
these reports has been the increasing resistance of pathogenic 
bacteria isolated from clinical specimens to antibiotics com-
monly used within the hospital communities.19
The World Health Organization (WHO) has called 
antibiotic resistance an emerging disease.20 Bacteria may be 
innately resistant or may acquire resistance to antibiotics. 
The rapid spread of bacterial resistance to antimicrobial 
agents has led to the search for newer and more potent 
drugs. However, as soon as new drugs appear, irrational use 
and abuse of them causes bacterial resistance. An extensive 
body of clinical research confirms that the fluoroquinolones 
are extremely effective for the treatment of UTIs ranging 
in severity from uncomplicated cystitis to urosepsis.21 
The superiority of ciprofloxacin compared to trimethoprim/
sulfamethoxazole has also been confirmed in patients with 
acute pyelonephritis.22
Of the newer fluoroquinolones, only levofloxacin is 
approved for both upper and lower UTIs. It should be 
emphasized that some other quinolones may demonstrate 
high activity against some Gram-negative organisms, 
and hence may be indicated for the treatment of these 
organisms implicated in UTI. Based on the emerging abuse 
of fluoroquinolone drugs and bacterial resistance in recent 
times, it becomes increasingly imperative to monitor drug 
resistance over a period of time.
Materials and methods
sampling and ethical consideration
Mid-stream urine samples were collected from patients 
attending clinics for treatment of UTI. Clinical information 
on the patients included pain during urination, penal and 
vaginal discharge, urethral and vaginal itching, foul vaginal 
smell, and urethral irritation. Informed consent of all the 
patients were obtained by the heads of the various units 
in all the clinics sampled. All the patients during the four 
years of the study agreed to participate. Other necessary 
data regarding the patients were obtained from the clinical 
register. Samples were collected randomly from different 
hospitals and clinics in and around the Sapele Delta State of 
Nigeria during the years 2001, 2002, 2003, and 2004. The 
sample size was determined by dividing the average number 
of patients visiting each clinic for UTI per year by the total 
number of the clinics where samples were collected.
Procedure
The urine samples were immediately cultured onto nutrient 
agar, McConkey agar, blood agar, chocolate agar, Mannitol 
salt agar, and cystine lactose electrolyte-deficient (CLED) 
agar plates (Oxoid Ltd., Basingstoke, UK). All the samples 
were cultured in duplicate and incubated both aerobically and 
anaerobically at 37 °C (Weiss Gallenkamp, Loughborough, 
UK) for 24 hours. Bacterial count and identification were 
done according to the standard methods of Bergey’s manual,23 
Harrigan and McCane,24 and Cowan and colleagues.25
Antibiotic sensitivity tests were performed using the filter 
paper disc diffusion method.26 The quinolone drugs used were 
moxifloxacin, levofloxacin, ciprofloxacin, ofloxacin (Sigma-
Aldrich, St. Louis, MO, USA), pefloxacin, and nalidixic 
acid (Fidson Healthcare Plc, Lagos, Nigeria). They were all 
commercially obtained (Fidson Healthcare; Sigma-Aldrich). International Journal of General Medicine 2009:2 173
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The bacterial isolates were subcultured into peptone water 
before being used for antibiotic sensitivity tests as described 
by Cheesbrough.26 However, the plates with more than three 
different types of culture were regarded as contaminants and 
hence eliminated from the study. Only 15 of the samples had 
mixed growth of E. coli and Klebsiella spp., and 10 S. faecalis 
and E. coli. Zones of inhibition were read according to the 
method of Stroke and Ridway.27
An Oxford strain of S. aureus, NCTC 6571, was used as 
control for Gram-positive bacteria while an E. coli strain, 
NCTC 10418, was used as control for Gram-negative 
bacteria. The results were statistically analyzed using regres-
sion analysis using SPSS software (version 11; SPSS Inc., 
Chicago, IL, USA). The total number of bacterial isolates in 
each year was used as the dependent variable while the num-
ber of isolates per year was used as independent variables.
Results
A total of 1,100 patients within the age ranges of 20, 20–50 
and 50 years comprising of 520 (32.5%) males and 739 
(67.2%) females with clinical cases of UTI were sampled 
(Table 1). Age distribution shows that persons aged 20–50 years 
frequented general practice clinics for UTI treatment more 
often (822; 74.7%), which was followed by persons aged 
20 (165; 15%). From the samples, a total of 1,906 pure 
bacterial cultures were obtained with Gram-negative bacteria 
being predominant (Table 2). E. coli was the highest isolate 
(871; 45.7%). Other isolates were Proteus spp., Klebsiella 
spp., and P. aeruginosa. The Gram-positive bacteria isolated 
were relatively fewer and were mainly S. aureus and 
Streptococcus spp. However, there were 87 samples with 
mixed culture. Only 36 of these gave the same result after 
a repeated sample collection and were regarded as positive 
cultures. Of the total bacterial isolates, 80% grew aerobically 
while only 20% grew anaerobically.
The mean percentage of the isolates in all years sampled 
are shown in Table 3. The mean percentage of E. coli isolates 
resistant to all the quinolones used increased from 21.6% in 
2001 to 24.0% in 2002. In 2003, the mean resistance was 
28.1%, which rose to 68.7% in 2004, showing a 9.7% rise in 
resistance of E. coli to quinolones from 2001 to 2004. Also, 
for S. aureus there was a steady rise in resistance from 2001 to 
2004. All other organisms showed increased resistance except 
for Klebsiella spp., which showed a minimal decrease in 
resistance (0.9%) between 2001 and 2004. For P. aeruginosa, 
there was a marked increase in resistance to quinolones 
from 35.6% to 49.8%, showing a 14.2% rise in resistance. 
The summary of susceptibility and resistance profiles for 
all identified isolates (Table 4) shows that P. aeruginosa 
exhibited the highest resistance to all the quinolones with a 
mean of 43.4% resistant strains while Streptococcus spp. was 
most susceptible to the quinolones. Among the quinolone 
drugs, nalidixic acid was least efficient in preventing the 
growth of UTI pathogens with 51.7% of all isolates resistant, 
while ciprofloxacin was most potent, being able to prevent the 
growth of 91.2% of all the UTI pathogens tested. Statistical 
analysis showed that there was a relationship between isolates 
per year (R = 1.00; 95% confidence interval). There was also 
a significant difference in all the bacteria isolates per year 
(F = 369.404, 95% CI: p = 0.39).
Discussion
In spite of the reported efficacy of the quinolones tested in 
this study, some isolates were found to be resistant to some 
of these quinolones. However, some of the quinolones, 
particularly ciprofloxacin and levofloxacin proved to be of 
high therapeutic value. The inclusion of nutrient agar and 
McConkey agar in this study was because these agars are 
routinely used for isolation in the average Nigerian hospital 
laboratory, and we tried to mimic as much as possible the 
routine Nigerian laboratory processes. This study was also 
able to show that there is increase in resistance to the quino-
lone drugs in Nigeria and this will continue if not urgently 
arrested. The results obtained from the four years sampled 
showed increase in the number of resistant isolates over 
the years sampled (Table 3). This represents a major public 
Table 1 The percentage of the incidence rate of urinary tract 
infection according to age and sex
Sex Prevalence within age groups (%)
20 years 20–50 years 50 years Total
Male 100 (9.1%) 179 (16.3%) 82 (7.5%) 361 (32.8%)
Female 65 (5.9%) 643 (58.45%) 31 (2.8%) 739 (67.2%)
Total 165 (15%) 822 (74.7%) 113 (10.3%) 1100 (100%)
Table 2 Prevalence of bacteria isolates obtained from the studied 
population
Bacterial isolates No of isolates Percentage (%)
Escherichia coli 871 45.7
Proteus spp 286 15.0
Klebsiella spp 233 12.3
Pseudomonas aeruginosa 219 11.5
Staphylococcus aureus 193 10.1
Streptococcus spp 102 5.4
Total 1906 100%International Journal of General Medicine 2009:2 174
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health problem that requires drastic action for it to be properly 
controlled as earlier reported by Ozerek and Roa.20 This study 
also reveals that P. aeruginosa, though isolated in fewer 
numbers, is gradually taking over as a major public health 
problem since this bacteria presents the highest resistance 
of all the bacteria isolated in this part of Nigeria. There have 
also been other studies which show the high drug resistance 
of P. aeruginosa in Nigeria19 (Table 4) as well as showing 
the most rapid rise in resistance (Table 3). This does not 
undermine E. coli as the most prevalent bacteria in UTI as 
earlier reported by Orenstein and Wong28 and Lutters and 
colleagues,29 who reported that the UTI may be endogenous 
or exogenous. S. aureus was the most prevalent Gram-
positive bacteria isolated with a mean percentage of 10.1% 
(Table 2). The advantage of this study is that it looked at 
the rate of increase of bacteria drug-resistant to quinolones, 
which are a group of very effective drugs compared with 
earlier studies which only showed that organisms were 
drug-resistant22 but did not discuss the rates of increase. 
Our study shows that resistance to quinolones continues 
to increase. If urgent measures are not taken to arrest the 
situation, we may see the return of the era of the search for 
new drugs to fight bacterial infections.
Age group distribution showed that UTI was high among 
the group aged 20, which continued into the group aged 
20–50 (Table 1), probably because of the high sexual activity 
within this age group. More females were affected with UTI 
than their male counterparts (Table 1). This has been attributed 
to the shortness of the female urethra and the closeness of the 
vagina to the perianal region of the urethral meatus in females, 
and also due to the antibacterial activity of the prostatic fluid in 
males and the relative longer length of the male urethra.9,11,30
In summary, the susceptibility and resistance profiles of 
all isolates in this study have shown that ciprofloxacin and 
levofloxacin possess the highest efficacy among the quino-
lones while nalidixic acid is least therapeutic. Despite this 
efficacy, there was a general increase in the resistance pattern 
of isolates to all the quinolones used in this study. This was 
Table 3 Percentage (%) mean of quinolone resistant bacteria isolates obtained from the studied population from 2001 to 2004
S/no Isolate 2001 2002 2003 2004 Difference in resistance 
level from 2001–2004
1 Escherichia coli 21.6 24.0 28.1 31.3 9.7% Increase
2 Proteus spp 12.4 16.7 18.5 21.2 8.8% Increase
3 Klebsiella spp 11.3 12.0 11.2 10.4 0.9% Decrease
4 Pseudomonas aeruginosa 35.6 40.1 47.8 49.8 14.2% Increase
5 Staphylococcus aureus 5.5 8.2 12.7 15.3 9.8% Increase
6 Streptococcus faecalis 4.5 4.9 5.2 5.1 0.8% Increase





Number and percentage (%) of isolates sensitive or resistant to quinolones  Mean





125 (14.4)   
746 (85.6)
62 (7.1)  
809 (92.9)
122 (14.0)  
749 (86.0)
249 (28.6)  
622 (71.4)
311 (35.7)  
560 (64.3)
503 (57.7)   
368 (42.3)
229 (26.3)  
642 (73.7)




12 (4.3)  
274 (95.7)
11 (3.7)  
275 (96.3)
37 (12.9)  
249 (87.1)
36 (12.6)  
250 (87.4)
71 (24.8)  
215 (75.2)
126 ( 44.2)   
160 (55.8)






18 (7.6)  
217 (92.4)
12 (4.9)  
223 (95.1)
4 (1.6)  
231 (98.4)
22 (9.2)  
213 (90.8)
20 (8.5)  
215 (91.5)
78 (33.3)  
157 (56. 7)






127 (58.2)  
92 (41.8)
119 (54.4)  
100 (45.6)
2 (0.9)  
217 (99.1)
23 (10.5)  
196 (89.5)
126 (57.5)  
93 (42.5)
173 (79.1)  
46 (20.9)






1 (0.5)  
192 (99.5)
1 (0.7)  
192 (99.3)
1 (0.3)  
192 (99.7)
11 (5.5)  
182 (94.5)
17 (9)  
176 (91)






1 (1.2)  
101 (98.8)
1 (1.0)  
101 (99.0)
1 (1.1)  
101 (99.9)
4 (3.6)  
98 (96.4)
7 (7.1)  
95 (92.9)
17 (16.4) 5 (4.9)
Total (1906) R  
S
284 (14.9)  
1622 (85.1)
206 (10.8)  
1700 (89.2)
167 (8.8)  
1739 (91.2)
345 (18.1)  
1561 (81.9)
552 (29.0)  
1354 (71.0)
985 (51.7)   
921 (48.3)
423 (22.2)  
1483 (77.8)
Abbreviations: Cipro, ciprofloxacin; Levo, levofloxacin; Moxi, moxifloxacin; Nal. A., nalidixic acid; Oflo, ofloxacin; Peflo, pefloxacin; R, resistant; S, sensitive.International Journal of General Medicine 2009:2
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further confirmed by SPSS statistical analysis. However, 
in the course of treatment, cost, and side effects must also 
be considered especially concerning the low-income earners 
as high costs might discourage them from visiting clinics for 
proper examination and treatment. Drug abuse, which is a 
major source of multidrug resistance, must be discouraged and 
there should be continuous education of the general public on 
the need for rational use of drugs, particularly antimicrobial 
drugs. However, this is the first study of its type in Nigeria. 
The advantage of this study is that clinicians now know that 
some bacteria are becoming resistant to quinolones, which 
used to be the most valued drugs in this part of the world. This 
study also states the importance of carrying out sensitivity 
tests prior to treatment against the use of empirical treatment 
currently in practice in this locality.
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